Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation‐positive advanced cutaneous melanoma

The combination of dabrafenib and trametinib demonstrated encouraging antitumor activity and tolerability, at initial analysis, in Japanese patients with BRAF V600 mutant advanced melanoma warranting further investigation. This study evaluated the safety and tolerability, pharmacokinetics (PK) and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamazaki, Naoya, Tsutsumida, Arata, Takahashi, Akira, Namikawa, Kenjiro, Yoshikawa, Shusuke, Fujiwara, Yutaka, Kondo, Shunsuke, Mukaiyama, Akihira, Zhang, Fanghong, Kiyohara, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947742/
https://www.ncbi.nlm.nih.gov/pubmed/29399853
http://dx.doi.org/10.1111/1346-8138.14210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947742/
https://www.ncbi.nlm.nih.gov/pubmed/29399853
http://dx.doi.org/10.1111/1346-8138.14210

Ejemplares similares